MCK Q1 growth and Precision Medicine Group acquisition lift outlook
MCK cited strong Q1 growth across key segments, with AI and automation driving productivity. Strategy highlights oncology/biopharma/supply chain and the $2.25B Precision Medicine Group acquisition.
25B Precision Medicine Group acquisition. Q1 delivered strong growth across key segments, with AI and automation driving productivity. Stable generics, biosimilar opportunities, and disciplined capital deployment suppo…